Home » Galvanize Therapeutics Electrical Pulse System Shows Promise in NSCLC Patients
Galvanize Therapeutics Electrical Pulse System Shows Promise in NSCLC Patients
November 11, 2022
Patients with non-small cell lung cancer (NSCLC) treated with Galvanize Therapeutics’ Aliya pulsed electric field (PEF) system showed more immune response than the non-treated control group, according to initial results from an ongoing trial presented at the Society for Immunotherapy of Cancer's annual meeting in Boston, Nov. 8-12.
To View This Article:
Subscribe To Device Daily Bulletin Premium
Device Daily Bulletin Premium Subscription
Upgrade to Device Daily Bulletin Premium to get all the articles in the free publication PLUS more in-depth stories on regulatory and industry developments, FDA inspection and enforcement activities and analysis of market trends. It makes sense of everything successful devicemakers must know and do, delivering the news, analysis and interpretation of industry changes you need to stay compliant and thrive. And it’s combined with timely content from FDAnews management reports and webinars. Learn more